DEFR14A: LAVA Therapeutics Amends Proxy Statement, Proposes KPMG as New Auditor for 2025 Fiscal Year and Addresses Remediated Internal Control Weaknesses

LAVA Therapeutics N.V. has filed an amended definitive proxy statement for its 2025 Annual General Meeting, notably proposing a change in its external auditor from PricewaterhouseCoopers to KPMG for the 2025 financial year and addressing previously remediated material weaknesses in internal controls.

Summary

• The Annual General Meeting (AGM) of LAVA Therapeutics N.V. is scheduled for June 11, 2025, at 2:00 p.m. Central European Summer Time in Utrecht, the Netherlands.
• The record date for voting at the AGM is May 14, 2025, and the cut-off time for attendance notification and proxy submission is June 4, 2025, at 11:59 p.m. Eastern Time.
• A key proposal involves the appointment of KPMG Accountants N.V. as the company's external auditor for Dutch law purposes and KPMG LLP as the independent registered public accounting firm for the financial year 2025, replacing PricewaterhouseCoopers Accountants N.V.
• PricewaterhouseCoopers Accountants N.V. was dismissed on May 20, 2025; their reports for fiscal years 2023 and 2024 contained no adverse opinions or qualifications, except for previously disclosed material weaknesses in internal control over financial reporting.
• The material weaknesses related to inadequate general controls over information technology (lack of change management, software development life procedures, insufficient user access controls) and the ability to design and maintain appropriate segregation of duties were remediated as of December 31, 2024.
• Other proposals for the AGM include the adoption of the company's Dutch statutory annual accounts for the financial year 2024, the release of board members from liability for their duties during 2024, and the extension of authorization for the board to acquire shares (or depository receipts) up to 10% of issued share capital.
• The reappointment of Jay Backstrom and James Noble as non-executive directors for terms ending in 2028 is also on the agenda.
• The Board of Directors unanimously recommends a vote 'FOR' all proposals.
• Executive compensation for 2024 includes Stephen Hurly (CEO) at $1,206,061, Fred Powell (CFO) at $730,202, and Charles Morris (CMO) at $851,409.
• The company's 2024 corporate goal attainment was 70%, influencing non-equity incentive plan compensation.
• As of March 31, 2025, there are 26,305,295 shares outstanding, with 644,532 shares remaining available for future issuance under equity compensation plans.
• Significant beneficial owners include Cooperative Gilde Healthcare IV UA (20.6%), Versant Ventures (17.4%), Redmile Group, LLC (7.9%), BML Investment Partners, L.P. (7.4%), and Sanofi Foreign Participations B.V. (7.3%).

Sentiment

Score: 7

Explanation: The document is a routine proxy statement for an Annual General Meeting, indicating normal corporate operations. The remediation of previously identified material weaknesses in internal controls is a positive development, and the proposed change in auditor is presented as a matter of good corporate practice without underlying disputes. The proposals are standard for an AGM, and the board recommends voting 'FOR' all of them, suggesting internal alignment and stability.

Positives

• Remediation of material weaknesses in internal control over financial reporting as of December 31, 2024, indicating improved financial oversight.
• The Board's unanimous recommendation for all proposals suggests strong internal alignment and confidence in the proposed actions.
• Extension of authorization for share repurchases up to 10% of issued share capital provides the company with flexibility for capital management and potential value creation.
• The reappointment of experienced non-executive directors, Jay Backstrom and James Noble, ensures continuity and expertise on the Board.
• The company maintains robust corporate governance practices, including an independent, non-executive Board Chair and fully independent Audit, Compensation, and Nomination and Corporate Governance Committees.

Negatives

• The prior existence of material weaknesses in internal control over financial reporting, although remediated, highlights past deficiencies in financial oversight.
• The change in auditor from PricewaterhouseCoopers to KPMG, while stated as a matter of good corporate practice, could be perceived by some as a potential signal of increased scrutiny, despite the company reporting no disagreements with the former auditor (other than the remediated material weaknesses).

Risks

• The potential for a quorum not to be present at the AGM could necessitate a new meeting, causing delays and additional expenses.
• Shareholder proposals that do not comply with the company's articles of association and applicable laws may be rejected or ruled out of order.
• While remediated, the historical material weaknesses in internal control over financial reporting (inadequate general controls over IT, lack of change management/software development life procedures, insufficient user access controls, and inability to design/maintain appropriate segregation of duties) indicate areas that required significant attention and could pose a risk if not continuously monitored.

Future Outlook

The document primarily focuses on the upcoming Annual General Meeting (AGM) and related corporate governance matters. It outlines the agenda for the AGM, including the adoption of 2024 financial accounts, auditor appointments for 2025, and director reappointments. The company intends to announce whether the proposals have passed at the AGM and will report the final voting results in a Current Report on Form 8-K within four business days after the meeting. It also provides the deadline for shareholder proposals for the 2026 AGM, indicating standard forward planning for corporate events. No specific financial guidance or strategic business outlook beyond these operational aspects is provided.

Management Comments

• Stephen Hurly, Chief Executive Officer: "Thank you for your support."
• The Board of Directors: "The Board unanimously recommends a vote FOR all Proposals."
• The Board of Directors: "The Board believes that separation of the positions of the Chair and CEO reinforces the independence of the Board in its oversight of the business and affairs of the Company but reserves the flexibility to determine whether to keep the roles of Chair and CEO separated."
• The Board of Directors: "We believe that the leadership structure of our Board is appropriate and enhances its ability to effectively carry out its roles and responsibilities."

Industry Context

This SEC filing is a standard definitive proxy statement (Schedule 14A) for an Annual General Meeting, a routine disclosure for publicly traded companies across all industries. For LAVA Therapeutics, a biotechnology company, the document highlights the ongoing importance of robust financial controls and regulatory compliance, as evidenced by the remediation of internal control weaknesses and the change in external auditors. The re-election of non-executive directors with extensive experience in the life sciences, particularly in oncology and drug development (e.g., Dr. Jay Backstrom from Scholar Rock, Acceleron Pharma, Celgene; James Noble from Adaptimmune, Immunocore), underscores the specialized expertise required for board oversight in the highly regulated and scientifically complex pharmaceutical and biotechnology sectors. The proposals reflect typical corporate governance activities aimed at maintaining operational integrity and shareholder alignment within the industry's regulatory framework.

Comparison to Industry Standards

• LAVA Therapeutics' corporate governance structure, featuring an independent, non-executive Chair and fully independent Audit, Compensation, and Nomination and Corporate Governance Committees, aligns with best practices and Nasdaq listing standards for publicly traded companies, including those in the biotechnology sector.
• The company's policy of separating the roles of Chair and CEO is a common governance standard adopted by many mature public companies to enhance board independence and oversight, comparable to practices seen across the industry.
• The authorization for the Board to acquire up to 10% of the company's issued share capital is a standard capital management tool, similar to share repurchase programs utilized by other public companies, providing flexibility for capital allocation and potential shareholder value enhancement.
• The remediation of previously identified material weaknesses in internal control over financial reporting demonstrates the company's commitment to meeting SEC and PCAOB standards, a critical and common focus area for companies, particularly those in growth phases or subject to stringent regulatory scrutiny, aligning with industry expectations for financial integrity.

Corporate Governance

Related Party Transactions

• Employment agreements with named executive officers (Stephen Hurly, Fred Powell, Charles Morris) detailing their compensation, severance, and change in control benefits.
• Indemnification agreements with all current and former directors, requiring the company to indemnify them to the fullest extent permitted by law.

Stakeholder Impact

• **Shareholders**: Directly impacted by the voting on proposals, including the appointment of the new auditor, re-election of directors, and authorization for share repurchases. The remediation of internal control weaknesses is a positive for shareholder confidence in financial reporting.
• **Employees**: Affected by executive compensation policies, equity incentive plans, and the overall corporate governance framework, which aims to align management incentives with company performance.
• **Auditors**: PricewaterhouseCoopers Accountants N.V. is dismissed, concluding their engagement, while KPMG Accountants N.V. and KPMG LLP are appointed, initiating new audit relationships with the company.
• **Management**: Executive officers' compensation and severance terms are detailed, and the Board's oversight structure directly impacts their roles and responsibilities.

Next Steps

• Shareholders are urged to vote their shares prior to the AGM by phone, internet, or mail, or in person at the meeting.
• The Annual General Meeting of Shareholders will be held on June 11, 2025, to vote on the proposed agenda items.
• The company plans to announce whether the proposals have passed at the AGM and will report the final voting results in a Current Report on Form 8-K within four business days after the meeting.
• Shareholders intending to submit proposals for the 2026 Annual General Meeting under Rule 14a-8 must do so by January 27, 2026.

Key Dates

Recommendation

Keywords

LAVA Therapeutics, SEC filing, proxy statement, Annual General Meeting, AGM, auditor change, KPMG, PricewaterhouseCoopers, corporate governance, internal controls, financial reporting, share repurchase, executive compensation, board of directors, biotechnology, pharmaceutical